General Anesthesia Drugs Market Growth, Size, Trends, Price, Revenue, Demand and Future Outlook: SPER Market Research

Q: How can I get the sample report on the Anesthesia Drug Market?

You can get the sample pages by clicking the link - Click Here

Published: Nov 2022	Report ID: PHAR2211	Pages: 1 - 230	Formats^*:
Category : Pharmaceutical

General Anesthesia Drugs Market Introduction and Overview

According to SPER Market Research, the Global General Anesthesia Drugs Market is estimated to reach USD 8.59 billion by 2033 with a CAGR of 3.73%.

The report includes an in-depth analysis of the Global General Anesthesia Drugs Market, including market size and trends, product mix, distribution channels, and supplier analysis. General anesthesia drugs are medications used to induce a reversible state of unconsciousness and immobility in patients during surgical procedures. These drugs act on the central nervous system, suppressing consciousness, pain perception, and muscle reflexes. They are administered by trained healthcare professionals and help ensure patient comfort, facilitate surgery, and maintain vital signs throughout the procedure.

January 2022: Akorn Operating Company LLC has agreed to sell seven branded ophthalmic products to Laboratories Théa SAS. Théa will be able to add Akorn-branded medicines to its portfolio, including Akten (lidocaine HCl ophthalmic gel), a local anaesthetic recommended for ocular surface anaesthesia during ophthalmologic operations, as a result of the strategic move.

Propofol is one of the most regularly used general anaesthetics in surgery and is used as a sedative in the ICU for critical care patients (particularly those with COVID-19). It is used to start and keep procedural sedation, general anaesthesia, and so on going. The US Food and Drug Administration authorised the use of Fresenius Propoven 2% emulsion to sustain sedation in COVID-19 patients (16 years and older) requiring mechanical breathing in June 2020.

Market Opportunities and Challenges

One of the significant market opportunities in the global general anesthesia drugs market is the increasing demand for outpatient surgeries. As advancements in medical technology and surgical techniques continue to evolve, there is a growing trend towards performing surgeries on an outpatient basis. This creates a need for shorter-acting and rapid-recovery anesthesia drugs that allow patients to recover quickly and safely, enabling them to return home the same day. Meeting this demand presents an opportunity for drug manufacturers to develop and market anesthesia drugs specifically tailored for outpatient procedures.

The possible risk of side effects and problems associated with anaesthesia administration is one of the primary issues in the worldwide general anaesthesia medications market. Respiratory depression, cardiovascular instability, allergic responses, and post-operative cognitive impairment are among dangers of anaesthesia. To ensure patient safety and minimise these hazards, rigorous patient evaluation, adequate medication selection, precise dose determination, and constant monitoring throughout the anaesthesia procedure are required. Developing and improving anaesthesia medications with enhanced safety profiles while minimising possible consequences is a major issue for industry companies.

Get more information on this report: Download Free Sample PDF

Market Competitive Landscape

The anaesthesia pharmaceuticals industry is quite competitive, with numerous large competitors. However, as medicine approvals increase, mid-sized to smaller firms are growing their market position by releasing novel components at lower prices. The key players in the global General Anesthesia Drugs market include Akorn, Novartis AG, Glaxo SmithKline Plc, Fresenius Se & Co KGaA, F. Hoffmann- La Roche, Astra Zeneca Plc, Piramal Enterprises Ltd., Pfizer Inc., Par Pharmaceuticals, Merck & Co Inc., Sanofi, Teva Pharmaceuticals, Bayer AG, Abbvie, Abbott Laboratories, Others.

Scope of the Report:

Report Metric	Details
Market size available for years	2019-2033
Base year considered	2022
Forecast period	2023-2033
Segments covered	By Product, By Mobility, By Mode, By End User
Regions covered	Asia-Pacific, Latin America, Europe, Middle East and Africa, North America
Companies Covered	Akorn, Novartis AG, Gilead Science Inc., Glaxo SmithKline Plc, Fresenius Se & Co KGaA, F. Par Pharmaceuticals, Hoffmann- La Roche, Sanofi, Merck & Co Inc., Astra Zeneca Plc, Baxter International Inc., Apotex, Heritage Pharmaceutical Inc., Pfizer Inc., Piramal Enterprises Ltd., Hikma Pharmaceuticals Plc, Teva Pharmaceuticals, Bayer AG, Abbvie, Abbott Laboratories, Others

COVID-19 Impact on Global General Anesthesia Drugs Market

The worldwide anaesthesia medication industry was significantly impacted by COVID-19. Because of the interruption in surgical operations, non-emergency surgeries were postponed or cancelled, resulting in lower demand for anaesthesia medicines. To reduce the danger of viral transmission, healthcare practitioners moved to alternate anaesthesia procedures such as regional anaesthesia and local anaesthesia, affecting demand for general anaesthesia medicines. Supply chain interruptions induced by lockdown measures and manufacturing issues resulted in anaesthesia medicine shortages, affecting patient care and surgical operations even more. These impacts emphasise the difficulties that the anaesthesia medication market experienced during the epidemic.

Key Target Audience

Academic and Research Institutions
Healthcare Providers
Hospitals and Surgical Centres
Regulatory Authorities
Anesthesiologists and Anesthesia Providers
Pharmaceutical Companies
Medical Device Manufacturers
Others

Our in-depth analysis of the General Anesthesia Drugs Market includes the following segments:

By Drug Type:	Desflurane Dexmedetomidine Midazolam Propofol Remifentanil Sevoflurane Others
By Route of Administration:	Inhalation Intravenous
By Surgery Type:	Cancer Surgery General Surgery Heart Surgery Knee and Hip Replacements
By End User:	Ambulatory Surgical Centres Hospitals

Key Topics Covered in the Report

Global General Anesthesia Drugs Market Size (FY’2023-FY’2033)
Outline of Global General Anesthesia Drugs Market
Segmentation of Global General Anesthesia Drugs Market By Drug Type (Desflurane, Midazolam, Sevoflurane, Propofol, Dexmedetomidine Remifentanil, Others)
Segmentation of Global General Anesthesia Drugs Market By Route of Administration (Intravenous, Inhalation)
Segmentation of Global General Anesthesia Drugs Market By Surgery Type (Cancer Surgery, Heart Surgery, Knee and Hip Replacements, General Surgery)
Segmentation of Global General Anesthesia Drugs Market By End User (Ambulatory Surgical Centres, Hospitals)
Statistical Snap of Global General Anesthesia Drugs Market
Expansion Analysis of Global General Anesthesia Drugs Market
Problems and Challenges in Global General Anesthesia Drugs Market
Competitive View of the Global General Anesthesia Drugs Market
Effects of Demonetization and COVID-19 on Global General Anesthesia Drugs Market
Details on Current Investment in Global General Anesthesia Drugs Market
Competitive Analysis of Global General Anesthesia Drugs Market
Prominent Players in the Global General Anesthesia Drugs Market
SWOT Analysis of Global General Anesthesia Drugs Market
Global General Anesthesia Drugs Market Future Projections and Outlook (FY’2023-FY’2033)
Recommendations from Analyst

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1. Research data source

2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPER’s internal database
2.1.4. Premium insight from KOL’s

2.2. Market size estimation

2.2.1. Top-down and Bottom-up approach

2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity and Challenges analysis

4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities

4.1.4. Challenges

4.2. COVID-19 Impacts of the Global General Anesthesia Drugs Market

5. Market variable and outlook

5.1. SWOT Analysis

5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats

5.2. PESTEL Analysis

5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape

5.2.5. Environmental Landscape
5.2.6. Legal Landscape

5.3. PORTER’s Five Forces

5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry

5.4. Heat Map Analysis

6. Competitive Landscape

6.1. Global General Anesthesia Drugs Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global General Anesthesia Drugs Market

7. Global General Anesthesia Drugs Market, By Drug Type (USD Million)

7.1. Global General Anesthesia Drugs Market Value Share and Forecast, By Drug Type, 2023-2033
7.2. Desflurane
7.3. Dexmedetomidine
7.4. Midazolam
7.5. Propofol
7.6. Remifentanil
7.7. Sevoflurane
7.8. Others

8. Global General Anesthesia Drugs Market, By Route of Administration (USD Million)

8.1. Global General Anesthesia Drugs Market Value Share and Forecast, By Route of Administration, 2023-2033
8.2. Inhalation
8.3. Intravenous

9. Global General Anesthesia Drugs Market, By Surgery Type (USD Million)

9.1. Global General Anesthesia Drugs Market Value Share and Forecast, By Surgery Type, 2023-2033
9.2. Cancer Surgery
9.3. General Surgery
9.4. Heart Surgery
9.5. Knee and Hip Replacements

10. Global General Anesthesia Drugs Market, By End User (USD Million)

10.1. Global General Anesthesia Drugs Market Value Share and Forecast, By End User, 2023-2033
10.2. Ambulatory Surgical Centres
10.3. Hospitals

11. Global General Anesthesia Drugs Market Forecast, 2019-2033 (USD Million)

11.1. Global General Anesthesia Drugs Market Size and Market Share

12. Global General Anesthesia Drugs Market, By Drug Type, 2019-2033 (USD Million)

12.1. Global General Anesthesia Drugs Market Size and Market Share By Drug Type (2019-2026)
12.2. Global General Anesthesia Drugs Market Size and Market Share By Drug Type (2027-2033)

13. Global General Anesthesia Drugs Market, By Route of Administration, 2019-2033 (USD Million)

13.1. Global General Anesthesia Drugs Market Size and Market Share By Route of Administration (2019-2026)
13.2. Global General Anesthesia Drugs Market Size and Market Share By Route of Administration (2027-2033)

14. Global General Anesthesia Drugs Market, By Surgery Type, 2019-2033 (USD Million)

14.1. Global General Anesthesia Drugs Market Size and Market Share By Surgery Type (2019-2026)
14.2. Global General Anesthesia Drugs Market Size and Market Share By Surgery Type (2027-2033)

15. Global General Anesthesia Drugs Market, By End User, 2019-2033 (USD Million)

15.1. Global General Anesthesia Drugs Market Size and Market Share By End User (2019-2026)
15.2. Global General Anesthesia Drugs Market Size and Market Share By End User (2027-2033)

16. Global General Anesthesia Drugs Market, By Region, 2019-2033 (USD Million)

16.1. Global General Anesthesia Drugs Market Size and Market Share By Region (2019-2026)
16.2. Global General Anesthesia Drugs Market Size and Market Share By Region (2027-2033)
16.3. Asia-Pacific

16.3.1. Australia
16.3.2. China
16.3.3. India
16.3.4. Japan
16.3.5. South Korea
16.3.6. Rest of Asia-Pacific

16.4. Europe

16.4.1. France
16.4.2. Germany
16.4.3. Italy
16.4.4. Spain
16.4.5. United Kingdom
16.4.6. Rest of Europe

16.5. Middle East and Africa

16.5.1. Kingdom of Saudi Arabia
16.5.2. United Arab Emirates
16.5.3. Rest of Middle East & Africa

16.6. North America

16.6.1. Canada
16.6.2. Mexico
16.6.3. United States

16.7. Latin America

16.7.1. Argentina
16.7.2. Brazil
16.7.3. Rest of Latin America

17. Company Profile

17.1. Abbott Laboratories

17.1.1. Company details
17.1.2. Financial outlook
17.1.3. Product summary
17.1.4. Recent developments

17.2. Abbvie

17.2.1. Company details
17.2.2. Financial outlook
17.2.3. Product summary
17.2.4. Recent developments

17.3. Akorn

17.3.1. Company details
17.3.2. Financial outlook
17.3.3. Product summary
17.3.4. Recent developments

17.4. Apotex

17.4.1. Company details
17.4.2. Financial outlook
17.4.3. Product summary
17.4.4. Recent developments

17.5. Astra Zeneca Plc

17.5.1. Company details
17.5.2. Financial outlook
17.5.3. Product summary
17.5.4. Recent developments

17.6. Baxter International Inc.

17.6.1. Company details
17.6.2. Financial outlook
17.6.3. Product summary
17.6.4. Recent developments

17.7. Bayer AG

17.7.1. Company details
17.7.2. Financial outlook
17.7.3. Product summary
17.7.4. Recent developments

17.8. F. Hoffmann- La Roche

17.8.1. Company details
17.8.2. Financial outlook
17.8.3. Product summary
17.8.4. Recent developments

17.9. Fresenius Se & Co KgaA

17.9.1. Company details
17.9.2. Financial outlook
17.9.3. Product summary
17.9.4. Recent developments

17.10. Gilead Science Inc.

17.10.1. Company details
17.10.2. Financial outlook
17.10.3. Product summary
17.10.4. Recent developments

17.11. Glaxo SmithKline Plc

17.11.1. Company details
17.11.2. Financial outlook
17.11.3. Product summary
17.11.4. Recent developments

17.12. Heritage Pharmaceutical Inc.

17.12.1. Company details
17.12.2. Financial outlook
17.12.3. Product summary
17.12.4. Recent developments

17.13. Hikma Pharmaceuticals Plc

17.13.1. Company details
17.13.2. Financial outlook
17.13.3. Product summary
17.13.4. Recent developments

17.14. Merck & Co Inc.

17.14.1. Company details
17.14.2. Financial outlook
17.14.3. Product summary
17.14.4. Recent developments

17.15. Novartis AG

17.15.1. Company details
17.15.2. Financial outlook
17.15.3. Product summary
17.15.4. Recent developments

17.16. Par Pharmaceuticals

17.16.1. Company details
17.16.2. Financial outlook
17.16.3. Product summary
17.16.4. Recent developments

17.17. Pfizer Inc.

17.17.1. Company details
17.17.2. Financial outlook
17.17.3. Product summary
17.17.4. Recent developments

17.18. Piramal Enterprises Ltd.

17.18.1. Company details
17.18.2. Financial outlook
17.18.3. Product summary
17.18.4. Recent developments

17.19. Sanofi

17.19.1. Company details
17.19.2. Financial outlook
17.19.3. Product summary
17.19.4. Recent developments

17.20. Teva Pharmaceuticals

17.20.1. Company details
17.20.2. Financial outlook
17.20.3. Product summary
17.20.4. Recent developments

17.21. Others

18. List of Abbreviations

19. Reference Links

20. Conclusion

21. Research Scope

SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.

The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.

SPER-Methodology-1

SPER-Methodology-2

SPER-Methodology-3

Frequently Asked Questions About This Report

How big is the Anesthesia Drug Market?

The General Anesthesia Drugs Market is projected to reach USD 8.59 billion by 2033, growing at a CAGR of 3.73% during the forecast period.

What is the growth rate of the Anesthesia Drug Market?

The General Anesthesia Drugs Market grew in market size from 2023. The Market is expected to reach USD 8.59 billion by 2033, at a CAGR of 3.73% during the forecast period.

What is the anticipated CAGR of the Anesthesia Drug Market during the forecast period?

The General Anesthesia Drugs Market CAGR of 3.73% during the forecast period.

How can I get the sample report on the Anesthesia Drug Market?

You can get the sample pages by clicking the link - Click Here

What is the market size of the Anesthesia Drug Market in 2033?

The General Anesthesia Drugs Market size is USD 8.59 billion from 2023 to 2033.

Which segment is expected to lead the Anesthesia Drug Market during the forecast period?

The Anesthesia Drug Market segment is Covered By Drug Type, By Route of Administration, By Surgery Type, By End User.

Which region is expected to have the highest market share in the Anesthesia Drug Market?

The North America region is anticipated to have the highest market share in the Anesthesia Drug Market.

Who are the key players in Anesthesia Drug Market?

The key players in the market include Companies Covered Akorn, Novartis AG, Gilead Science Inc., Glaxo SmithKline Plc, Fresenius Se & Co KgaA, F. Hoffmann- La Roche, Astra Zeneca Plc, Piramal Enterprises Ltd., Pfizer Inc., Par Pharmaceuticals, Merck & Co Inc., Heritage Pharmaceutical Inc., Hikma Pharmaceuticals Plc, Baxter International Inc., Apotex, Sanofi, Teva Pharmaceuticals, Bayer AG, Abbvie, Abbott Laboratories, Others.

What is the conclusion of the Anesthesia Drug Market?

More consumers are turning to internet shops to make purchases, pay bills, and consult with doctors. This shift in consumer behaviour is projected to propel the general anaesthetic pharmaceutical market in the coming years.